Long-term Cardiovascular Risk Following Successful Renal Transplantation
NCT ID: NCT01728012
Last Updated: 2014-08-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
60 participants
OBSERVATIONAL
2012-11-30
2013-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Study of Long-term Deterioration of Kidney Transplants.
NCT00217126
Cardiovascular Risk Factors After Renal Transplantation in Children and Adults
NCT01008306
Multimorbidity and Cardiovascular Risk Factors After Renal Transplant
NCT07205692
Retrospective Study of Long-term Survival and Related Factors Among Kidney Transplant Recipients in China
NCT01796639
Resistive Index Measurements After Kidney Transplantation
NCT01879124
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
eGFR >=60ml/min/1.73m2
Patients with an estimated glomerular filtration rate of \>=60 ml/min/1.73m2.
No interventions assigned to this group
eGFR 45-60ml/min/1.73m2
Patients with estimated glomerular filtration rate \>=45 ml/min/1.73m2 and \<60ml/min/1.73m2.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documented elevated iPTH at Tx and 10 weeks post-tx
* Well functioning transplant 10 years following tx
* Signed informed consent
Exclusion Criteria
* Refused written informed consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Helse Stavanger HF
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Inger Hjørdis Bleskestad, MD
Role: PRINCIPAL_INVESTIGATOR
Helse Stavanger HF
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stavanger University Hospital
Stavanger, , Norway
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REK2010/2926
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.